News
10-21-2013, 06:30 AM
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
More... (http://www.news-medical.net/news/20131021/Verastem-presents-positive-results-from-VS-6063-clinical-and-preclinical-studies-at-2013-AACR-NCI-EORTC-meeting.aspx)
More... (http://www.news-medical.net/news/20131021/Verastem-presents-positive-results-from-VS-6063-clinical-and-preclinical-studies-at-2013-AACR-NCI-EORTC-meeting.aspx)